Featured News
Featured Hematology News.
Soliris® (eculizumab) Granted Orphan Drug Designation in Japan for the Treatment of Patients with Myasthenia Gravis
CHESHIRE, Conn. December 10, 2014 –(BUSINESS WIRE)–Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that Soliris® (eculizumab) has been granted orphan drug designation (ODD) by Japan’s Ministry of Health, Labour and Welfare (MHLW) for the treatment of patients with myasthenia gravis (MG), a rare, debilitating neurologic disorder. In patients with MG, uncontrolled complement activation due to antibodies […]
New Data Presented at ASH Annual Meeting Enhance Clinical Knowledge of aHUS and PNH and Underscore the Effectiveness of Soliris® (eculizumab) Treatment
New Analyses Report Clinical Benefits of Ongoing Soliris Therapy in Children and Adults with aHUS With or Without Identified Genetic Mutations Observational Data Highlight Importance of High Sensitivity Flow Cytometry to Enable Reliable Detection of PNH Cells CHESHIRE, Conn. December 8, 2014 –(BUSINESS WIRE)–Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that researchers presented data that continue […]
RainDance Forms Hematologic Oncology Consortium to Develop Assays for Liquid Biopsy Research of Myeloid Disorders
HemOnc experts validate unmet need and performance of new ThunderBolts Myeloid NGS Panel at ASH 2014 BILLERICA, Mass. — December 5, 2014 — RainDance Technologies, Inc., a genomics tools company simplifying the analysis of complex genetic diseases, today announced the formation of the RainDance HemOnc Consortium, composed of a select group of hematologic clinical research […]
Sequenta Launches New Online Results Portal for Physicians
Secure, real-time access to ClonoSIGHT™ test results, order status, patient MRD trends SOUTH SAN FRANCISCO, Calif. DECEMBER 4, 2014 – Sequenta, Inc. today announced the launch of its new physician portal, the ClonoSIGHT Secure Portal (https://results.clonosight.com). The HIPAA-compliant online portal enables physicians to more effectively integrate the ClonoSIGHT process, an ultra-sensitive, next-generation sequencing-based technology for […]
NICE Issues Final Positive Recommendation for National Commissioning of Soliris® (eculizumab) for All Patients with aHUS in England
Final Evaluation Determination Confirms that Soliris is a “Very Effective Treatment for aHUS with Significant Value to Patients” Final Evaluation Determination Includes the Same Conditions Discussed in Draft Recommendation, Including Establishment of an Expert Center and a Robust System to Monitor Patients Receiving Treatment CHESHIRE, Conn. November 27, 2014 –(BUSINESS WIRE)–Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today […]
Soliris® (eculizumab) Granted Orphan Drug Designation in Japan for the Treatment of Patients with Neuromyelitis Optical
CHESHIRE, Conn. November 25, 2014 –(BUSINESS WIRE)–Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that Soliris® (eculizumab) has been granted orphan drug designation (ODD) by Japan’s Ministry of Health, Labour and Welfare (MHLW) for the treatment of patients with neuromyelitis optica (NMO), a life-threatening, ultra-rare neurologic disorder. In patients with NMO, chronic, uncontrolled complement activation results in severe […]
Sequenta Enters Agreement with Illumina on In Vitro Diagnostic (IVD) Kit for Sequencing-Based Minimal Residual Disease Testing
SOUTH SAN FRANCISCO, Calif. NOVEMBER 17, 2014 – Sequenta, Inc., a biotechnology company developing clinical diagnostics based on immune cell receptor genes, today announced that the company has entered into an agreement with Illumina, Inc. (NASDAQ: ILMN). The purpose of the agreement is to commercialize an in vitro diagnostic (IVD) kit that will enable clinical […]
Longer-term Outcome Data from the Largest Prospective Trial of Soliris® (eculizumab) in aHUS Underscore the Effectiveness of Ongoing Soliris Treatment
– Multiple Clinical Presentations at Kidney Week 2014 – – Studies Report Clinical Benefits of Ongoing Soliris Therapy in Children and Adults Regardless of Dialysis or Transplant History – – New aHUS Registry Data Enhance the Understanding of aHUS – CHESHIRE, Conn. November 15, 2014 –(BUSINESS WIRE)–Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that researchers presented data […]